2026-11-06 22:22:05 UTC#593126newreportednews
Bristol Myers Squibb (BMY) stock news
Bristol Myers Squibb (BMY) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-11-05 08:00:00 UTC#578567updateconfirmednews
Schrödinger Q3 revenue beats estimates; Novartis deal expanded to $1.42B in milestones; Bunsen platform adopted
tradingviewimportance 0.40trust 0.70Schrödinger, Inc. +0.40Novartis AG +0.30Bristol Myers Squibb Company +0.20+2 entities
2026-11-03 15:25:06 UTC#564029updateconfirmednews
BioNTech raises full-year sales outlook on milestone payments from Bristol Myers Squibb cancer drug partnership
2026-11-03 12:16:48 UTC#562693newreportednews
Vested Finance identifies 10 US large-cap stocks trading at 47%-63% sector valuation discounts
zerodha pulseimportance 0.30trust 0.40Vested Finance 0Comcast Corporation +0.20AT&T Inc. +0.20+2 entities
2026-11-02 18:29:34 UTC#557387updateconfirmednews
Tempus AI projects 2026 revenue of $1.60B-$1.605B, targeting $65M adjusted EBITDA with BMS collaboration
2026-11-02 11:05:16 UTC#554347newconfirmednews
Invesco S&P Ultra Dividend Revenue ETF (RDIV) added $239.2M in net equity on Oct. 29, led by $14.7M in Chevron
yahooimportance 0.30trust 0.60Invesco S&P Ultra Dividend Revenue ETF +0.20Chevron Corporation +0.30Target Corporation +0.20+1 entities
2026-10-30 09:56:00 UTC#544364newconfirmedanalysis
WSJ profiles management approach of Bristol Myers Squibb CEO
2026-10-29 16:40:28 UTC#539134updateconfirmednews
Bristol Myers Squibb projects 2026 EPS $6.35-$6.55, anticipates $1.5B-$2B Eliquis revenue decline in 2027
2026-10-29 14:32:47 UTC#538266duplicateconfirmednews
Bristol Myers Squibb Q3 revenue $13.1B beats estimates; FY26 revenue outlook raised to $49.75B-$50.25B
2026-10-29 14:24:30 UTC#538167duplicateconfirmednews
Bristol Myers Squibb Q3 revenue rises 7% on growth portfolio, FY26 revenue guidance raised
2026-10-29 11:28:50 UTC#536679duplicateconfirmednews
Bristol Myers Squibb raises full-year revenue outlook on growth in newer drug portfolio
2026-10-29 11:13:00 UTC#536592duplicateconfirmednews
Bristol Myers Squibb Raises Full-Year Revenue Outlook Following Q3 Results
2026-10-29 11:07:43 UTC#536549duplicateconfirmednews
Bristol Myers Squibb raises 2026 revenue outlook to $49.75B-$50.25B, lowers EPS guidance to $6.35-$6.55
2026-10-29 11:05:27 UTC#536456newconfirmeddata release
Bristol Myers Q3 2026: Rev $13.07B vs $12.71B est, Adj EPS $1.35 vs $1.12 est; FY EPS guidance lowered
first_squawkimportance 0.70trust 0.80Bristol Myers Squibb Company +0.40Revlimid +0.50Eliquis +0.30+2 entities
2026-10-29 11:01:44 UTC#536485duplicateconfirmednews
Bristol Myers raises 2026 revenue forecast while lowering EPS guidance due to charges
2026-10-27 09:12:00 UTC#519723updateconfirmednews
Hengrui Medicine out-licensing revenue growth driven by GSK and BMS payments
dow_jonesimportance 0.40trust 0.80Jiangsu Hengrui Medicine Co., Ltd. +0.40GSK plc +0.30Bristol-Myers Squibb Company +0.30
2026-10-27 08:41:36 UTC#519573newconfirmednews
Hengrui Pharma 9M net profit rises 20.4% on out-licensing gains, full-year innovative drug growth target lowered
reutersimportance 0.50trust 0.90Jiangsu Hengrui Medicine Co., Ltd. +0.40GSK plc +0.30Bristol-Myers Squibb Company +0.30
2026-10-27 08:11:18 UTC#519472duplicateconfirmednews
Cipla Q2 profit misses estimates at 8.78 billion rupees on weak US generic Revlimid sales
reutersimportance 0.40trust 0.90Cipla Ltd. -0.50Bristol-Myers Squibb Company -0.20Revlimid -0.40+1 entities
2026-10-26 07:47:00 UTC#513221duplicateconfirmednews
Bristol-Myers Squibb reports Iza-Bren doubles median PFS in Phase 3 Panku-Lung01 trial
reutersimportance 0.40trust 0.90Bristol-Myers Squibb Company +0.60izalontamab brengitecan +0.70Panku-Lung01 +0.60
2026-10-26 07:30:00 UTC#513128newconfirmednews